Truist Securities analyst Richard Newitter lowered the price target on Medtronic, Inc. (NYSE: MDT) to $111.00 (from $121.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View Analyst PT Change

Medtronic, Inc. (MDT) PT Lowered to $120 but BofA Securities Sees FY Guidance as RealisticMay 27, 2022 7:30 AM Medtronic, Inc. (MDT) PT Lowered to $121 at Deutsche BankMay 27, 2022 7:03 AM Medtronic, Inc. (MDT) PT Lowered to $122 at RBC CapitalMay 27, 2022 6:24 AM Medtronic, Inc. (MDT) PT Lowered to $117 at Cowen; FY23 Can Be a Year of Real Pipeline ProgressMay 27, 2022 6:21 AM Medtronic, Inc. (MDT) PT Lowered to $125 at StifelMay 27, 2022 6:13 AM UPDATE: Needham & Company Downgrades Medtronic, Inc. (MDT) to HoldMay 27, 2022 5:48 AM Medtronic, Inc. (MDT) PT Lowered to $117 at CFRAMay 26, 2022 1:13 PM Medtronic (MDT) Sinks 6% on Disappointing Earnings and Guidance as Macro Issues Weigh, Analyst Warns Issues Might Not Resolve 'Near Term'May 26, 2022 9:30 AM Form 8-K Medtronic plc For: May 26May 26, 2022 6:50 AM Medtronic (MDT) Misses Q4 EPS by 5c, Offers GuidanceMay 26, 2022 6:49 AM Medtronic (MDT) Raises Quarterly Dividend 7.9% to $0.68; 2.6% YieldMay 26, 2022 6:48 AM Medtronic reports full year and fourth quarter fiscal year 2022 financial results; announces 8% dividend increaseMay 26, 2022 6:46 AM Medtronic (MDT) and DaVita (DVA) to Form new Independent Kidney Technology CompanyMay 26, 2022 6:45 AM Medtronic and DaVita announce new kidney health technology companyMay 26, 2022 6:45 AM